In a report published Tuesday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on Gilead Sciences GILD, and raised the price target from $81.00 to $100.00.
In the report, Morgan Stanley noted, “Our avg. price/patient for US HCV rises ~15%, offset by ~5% cut in total patients (pts) treated in 2015 (~50% Y/Y incr), resulting in modest US HCV sales hikes. Our EU sales are now ~$5.5B in both 2015/2016E, up from ~$3.5B/~$4B.With 70-80% of 2014E ~$2B in EU sales coming from Germany, we expect contributions from France/Italy/Spain & the UK to beat least 50% of the German run-rate, suggesting >$4.5B in 2015E EU sales.”
Gilead Sciences closed on Monday at $105.56.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in